Effects of Oral α -Lipoic Acid on Blood Pressure and Inflammatory Factors in Overweight or Obese Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial

Subjects: A Dou-ble-Blind, To evaluate the effects of the antioxidant α-lipoic acid (ALA) after oral administration on blood pressure and inflammatory factors in overweight or obese subjects. Methods: This was a randomized, double-blind, placebo-controlled crossover clinical trial. A total of 103 subjects of Chinese Han ethnicity were randomly assigned into ALA (n=52) or placebo groups (n=51). Subjects in the ALA group were treated with oral ALA 1200 mg/day for 8 weeks, followed by a 4-week washout period, then received placebo for another 8 weeks. Subjects in the placebo group were administered with placebo for 8 weeks, followed by a 4-week washout period and another 8-week treatment with ALA (1200mg/day). Result: protein (-0.85±5.92μg/ml p=0.884), blood (5.44±8.96mmHg vs.


Introduction
Recently, the prevalence of obesity has rapidly increased around the world, which is considered the most important cause for the dramatic increase in the incidence of cardiovascular disease (CVD) and type 2 diabetes (T2D). Obesity is a significant risk factor leading to CVD and T2D [1][2][3]. Although the influence of obesity as an independent risk factor for CVD is still controversial and requires further research, individuals with obesity are often complicated by metabolic syndrome (MetS), such as hypertension, hyperlipemia, and impaired glucose regulation, which can increase the risk of CVD onset and lead to significantly increased cardiovascular morbidity and mortality [4,5].
It has previously been found that there is a significant positive correlation between biomarkers of oxidative stress (OS) and body mass index (BMI) [6]. OS caused by obesity has been shown to have a crucial role in the development of CVD, such as atherosclerosis, coronary heart disease (CHD), and hypertension, and is regarded as the pathogenic mechanism underlying CVD and diabetes [7,8]. Several studies have shown that obesity is independently associated with OS [6,9,10]. Elevated levels of OS in obese subjects can increase vascular endothelial permeability, destroy vascular structure and endothelial function, and lead to increased wall thickness, lumen narrowing, and increased vasoconstriction, thereby resulting in the development of CVD [11,12]. In addition, obesity also represents a state of chronic low-level inflammation [13,14]. The inflammatory responses in obese subjects, which also result from OS, increase with the obesity [15], and OS could activate the pathway related to inflammatory responses. It has been shown that these inflammatory responses are involved in the development of atherosclerosis [16,17], and the incidence of CVD increases with the elevation of the inflammatory marker C-reactive protein (CRP) [18]. Thus, OS and inflammatory responses in obese subjects may be common mechanisms involved in the pathogenesis of obesityinduced CVD.
Collectively, these findings suggest that the multiple mechanisms involved in CVD and diabetes are associated with OS; and OS is a cause of endothelial cell injury and dysfunction, as well as CVD complications such as atherosclerosis. Therefore, antioxidant supplementation that is effective in reducing OS might be a strategy for the prevention and treatment of CVD. α-lipoic acid (ALA) is a powerful antioxidant with various antioxidant functions. ALA can improve endothelial function and reduce inflammatory markers in patients with MetS [19]. In addition, ALA has been shown to be effective in the treatment of diabetic polyneuropathy [20,21].
However, the role of ALA on CVD risk factors such as brachial-ankle pulse wave (baPWV), inflammatory factors, and blood pressure has not been fully elucidated. We therefore evaluate the effects of oral ALA on blood pressure and inflammatory factors in overweight or obese subjects, and the mechanisms of ALA were also explored. (3) subjects who had at least one type of the following diseases:
Subjects who met the following criteria were excluded from the study: a) Pregnant, lactating, or women of child-bearing age who were not using any method of contraception. b) Subjects with hypertension, diabetes, coronary artery disease (CAD) cancer, or liver disease.

c)
Subjects who could not understand the study or who refused to participate, and those with a psychiatric history were also excluded. A total of 347 subjects were preliminary screened, and 166 subjects who fulfilled the inclusion and exclusion criteria were enrolled. Written informed consent was obtained from 103 subjects, including 63 males and 40 females.

Randomization
This study was a randomized, double-blind, placebo-controlled crossover clinical trial. After consent was obtained, subjects were sequentially entered into the study using a blocked randomization schedule, and randomly assigned to two groups using Excel in a double-blind fashion, with a balanced sex ratio. The randomization sequence was generated by the principal investigators, and two investigators were in charge of registration and assignment.

Assessment
Before enrollment, all subjects underwent a medical examination. Baseline characteristics were collected after signed informed consent was obtained, and data were also collected at the end of the 8-, 12-(washout period), and 20-week interventions.
The baseline assessment included: general information

Physical Examination
Physical examination included height, body weight, and waist and hip circumference which was assessed on an empty stomach, with shoes and heavy clothing removed. BMI was calculated as weight (kg)/height (m 2 ). Blood pressure was measured according to the recommendations of the American Heart Association, and right upper arm blood pressure was observed using a mercury sphygmomanometer by qualified investigators.

Pulse Wave Velocity (PWV) Measurement
The brachial-ankle pulse wave velocity (baPWV) was measured using a VP-1000 device (Model BP203RPE, type II PWV/ABI; Omron, Japan) by a specialist from Xinjiang Medical University, Urumqi, China.

Blood Collection and Biochemical Indices Measurement
Venous blood was collected in the early morning on an empty

Statistical Analysis
Databases were created in Microsoft Access and error correction was carried out after double data entry. All statistical analyses were performed using Stata version 11.0, and all measurement data were expressed as mean±standard deviation (SD). After normal transformation, the non-normal distribution data were conducted with statistical disposal. Baseline data were compared with independent sample t-tests. After adjustment of treatment sequence and period, baseline values, sex and age, mixed effects models were used to compare the efficacy between the two groups. p values <0.05 were considered statistically significant.
Intention-to-treat was used for statistical analysis. For subjects who withdrew with measurements available before the intervention but not after the intervention, the differences were considered as '0' during statistical analysis. The mixed effects models were used to analyze the relationships between independent variables

Comparison of Baseline Characteristics
Enrolled subjects were randomly divided into two groups in a indices, and inflammation, were found to be comparable between the two groups (Tables 1).

Comparison of Baseline Dietary Intake
Baseline dietary intake for energy and the three main nutrients, including fat, protein and carbohydrates, as well as antioxidant nutrients such as vitamins A, C, and E and selenium, zinc and manganese, were distributed evenly and comparable between the two groups ( Table 2). there were significant changes in the levels of baPWV, SBP, DBP, CRP, IL-6 between the two groups before and after the intervention (p<0.05). After adjusting for differences in sex, age, treatment sequence and period, the results of mixed-effects models showed that the differences of SBP in the two groups were significant before and after the intervention (p<0.05), whereas there were no obvious differences for changes in the levels of baPWV, DBP, CRP and IL-6 between the two groups (Table 3), (p>0.05). Table 3: Intent-to-treat analysis of the markers of inflammation and blood pressure by adjusted mixed-effects models in the two groups (mean ± SD). Note: △: differences of levels after and before the intervention; a: logarithm transformation; ALA: α-lipoic acid.

Discussion
Obesity has been considered as a state of chronic OS and inflammation. OS and inflammatory responses in obese subjects may provide a common mechanism for the pathogenesis of obesity-induced CVD. IL-6 is a multifunctional cytokine and has been reported to be involved in regulating immune inflammatory responses and glucolipid metabolism. As an important mediator of immune responses, IL-6 has a central role in the regulation of inflammatory responses, which has effects on vascular walls leading to vascular wall injury. In addition, IL-6 is considered to have a crucial role in insulin resistance and atherosclerosis. CRP is an acute phase protein produced by the liver and can react with C-polysaccharide isolated from pneumococcal cell walls [22].

Several studies have suggested that CRP is a strong independent
predictor of future cardiovascular events [23,24]. As a hepatocytestimulating factor, CRP is a sensitive marker of inflammatory responses [25] and has been widely used to reflect inflammatory responses in clinical practice [26,27].
A recent study showed that OS is the common pathway involving ALA significantly reduced levels of IL-6 and improved endothelial function; however, no significant differences were found in the reduction of 8-iso-PGF2α levels [19]. In the present study, after oral administration of ALA at a daily dose of 1200mg for 8 weeks, no Because ALA transiently accumulates in vivo and is rapidly catabolized. In cell culture studies, the intracellular concentration of ALA following an oral dose was found to be several times higher than that in the plasma or tissues. So, typical cell culture conditions likely overestimate the direct antioxidant capacity of ALA.
Alternatively, ALA may act indirectly to maintain antioxidant status by enhancing the synthesis of endogenous antioxidants, rather than through a direct-acting antioxidant role in the body [30]. Glutathione (GSH) is a natural thiol antioxidant and substrate for detoxification enzymes, and studies have shown that ALA treatment can enhance GSH levels [31,32]. Secondly, oral administration of ALA has been shown to be less effective than intravenous injection. Compared with oral administration, intravenous infusion can increase insulin sensitivity in patients with T2D in a dose-dependent manner [33].
Finally, in the present study, the antioxidant properties of oral ALA intake at a daily dose of 1200mg were not strong enough to inhibit NF-κβ which could lead to vascular inflammation, so the pathways involved in the inflammatory responses were still active and the levels of inflammatory markers were not significantly reduced.
Recently Endothelin-1 is a vasoconstrictor produced by endothelial cells, and it has been shown that ALA can inhibit endothelin-1 overproduction in the kidney and blood vessels. Recent studies have also shown that ALA can improve NO synthesis, i.e., the main endothelial-derived vasodilator. Moreover, the onset of essential hypertension is also associated with abnormal ion transport across cell membranes. Various specific ion channels that are found in vascular smooth muscle cells maintain the dynamic balance of K + , Na + , and Ca 2+ ions between the intracellular and extracellular environments. The abnormality in ion transport increases the concentrations of intracellular Na + and Ca 2+ , reduces membrane potential, and activates the process of excitation-contraction coupling in smooth muscle cells (SMCs), which then increase vasoconstrictor reactivity and vascular resistance accompanied by an increase in SMC size. In animal models, ALA treatment given to rats with hypertension can reduce the release of cytoplasmic calcium and slow the changes in renal vessels, enabling DBP to return to normal levels. In the clinic, ALA in combination with acetyl-L-carnitine has been used in the treatment of MetS complicated by hypertension to enhance the anti-hypertensive effects associated with reduced DBP. By contrast, sola et al. found no significant changes in blood pressure compared after oral administration of ALA at a daily dose of 300mg in patients with MetS, compared with the placebo group (p>0.005) [19].
In the present study, overweight or obese subjects who completed 8 weeks of treatment with ALA showed a reduction in DBP. This is probably because ALA can activate eNOS, improve endothelial function, promote the release of NO, inhibit excessive endothelin-1 produced by the kidney and blood vessels, resulting in vasodilatation. Moreover, the possible mechanisms are also associated with increased levels of endogenous antioxidant markers caused by ALA treatment, which can maintain the dynamic balance of K + , Na + , and Ca 2+ on both sides of the cell membrane, correcting the abnormal ion transport. Epidemiological and other related studies have suggested that increased arterial stiffness is an independent risk factor for CVD and is also positively associated with atherosclerosis [34]. PWV is a useful measure of arterial stiffness and has been shown to be of great value in the evaluation of CVD [35,36]; therefore, we used PWV as one of the arterial stiffness indices in our clinic. In the present study, after treatment with ALA for 8 weeks, PWV in the ALA group was reduced to some extent compared with the placebo group, but the difference between the two groups was not significant (p>0.05). This might be due to the weaker antioxidant activity of ALA which could not completely inhibit NF-κβ so that the pathways involved in the inflammatory responses were still active and atherosclerosis had not been fully reversed. Above all, our results suggested that overweight or obese subjects who received ALA at a daily dose of 1200mg for 8 weeks showed a reduction in body weight. Nevertheless, further studies are needed to determine the possible mechanisms.
There were some limitations in the current study. The sample size may not be large enough. The SD of each measurement data was large, whereas differences in the means between the two groups were lower. Large intra-group differences and lower intergroup differences showed that the estimation of sample size in our study was lower than assumed. In addition, the length of the trial was relatively short. Another clinic trial has determined the effects of 600mg of ALA given intravenously over 12 weeks [21].
Although we adopted a double-dose regime in the present study, orally supplied ALA for a shorter time (8 weeks) may be insufficient to exert its effects.

Conclusion
At present, only a limited number of studies have examined the effects of antioxidants on cardiovascular risk factors in obese human subjects exist. In the present study, we carried out a randomized, double-blind, placebo-controlled crossover clinical trial to determine whether oral intake of ALA could reduce blood pressure and inflammatory factors. We found that after treatment with oral ALA at a dose of 1200mg for 8 weeks, The SBP was reduced, which could be considered as a novel therapy for hypertension. Our study could also provide further guidance for future clinical trials, although the changes in the biomarkers of inflammation and PWV levels were not significant. In order to determine the stronger effects of ALA on cardiovascular risk factors, multicenter research with a larger sample size, longer time of treatment, or increased dose of ALA is required.

Conflicts of Interest and Source of Funding
All the author declare they have no confict of interests. This study was supported by the Science and Technology Bureau Xinjiang Karamay (SK2009-09). We thank all the doctors, nurses of People's Hospital of Kelamay city, the postgraduates of college of public health of xinjiang medical university and the volunteers who joined in this study. We also thank the MRI (US) company for the free ALA pill and placebo.